Abstract: Objective To investigate the safety and efficacy recombinant human endostatin（endostar） durative transfusion combined with window period chemotherapy in advanced non-small cell lung cancer（NSCLC）. Methods From February 2012 to December 2013， 34 cases of ⅢB-Ⅳ NSCLC patients were treated with endostar（15mg／m2） durative transfusion combined with window period chemotherapy. Endostar was durative transfused every 24 hours for 7 days， and in the fourth day of the window period patients were received combined chemotherapy based on platinum， 21 days was a cycle. All patients were received 2-6 cycles； efficacy was evaluated every 2 cycles， and side effects were recorded every 1 cycle. Results Every patient was received at least 2 cycles， got 1 CR， 14 PR， 8 SD and 11 PD. The response rate（RR） of 34 patients was 44.1％， and non-squamous carcinoma was 38. 9％， squamous carcinoma was 50.0％. Fistline treatment of patients showed higher RR（53.9％）. Major toxicities related with endostar were sinus tachycardia in1 case， and 1 case of hypertension. No serious side effects such as bleeding were observed. Conclusion Endostar（15mg／m2） durative transfusion combined with window period chemotherapy for NSCLC was safety and efficacy， and a large prospective randomized controlled clinical study is worth to carry out in future.